Over 53,000 cannabis studies exist on PubMed. We translate them into plain English so you can understand what the science actually says— without the medical jargon.
Medical cannabis has demonstrated efficacy for certain conditions including chemotherapy-induced nausea, chronic pain, and epilepsy, with the FDA approving cannabis-derived medications like Epidiolex. Evidence strength varies by condition.
Strongest evidence exists for chronic pain, nausea/vomiting, and epilepsy. Research on other conditions is promising but often limited by federal scheduling restrictions.
Research summaries based on peer-reviewed studies from PubMed and medical journals.
The strongest evidence supports cannabis treating chronic pain, chemotherapy-induced nausea, multiple sclerosis spasticity, and treatment-resistant epilepsy. Emerging research supports potential benefits for PTSD, anxiety, insomnia, and inflammatory conditions.
The National Academies of Sciences, Engineering, and Medicine reviewed over 10,000 studies and found conclusive or substantial evidence for specific therapeutic uses.
Condition support based on National Academies of Sciences 2017 report and subsequent research.
Yes, the FDA has approved Epidiolex, a CBD-derived medication, for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This makes Epidiolex the first FDA-approved cannabis-derived prescription drug.
Epidiolex approval in 2018 marked a significant milestone. Other CBD products sold as supplements are not FDA-approved for treating specific conditions.
FDA approval per official FDA drug approvals database, June 2018.
Substantial evidence shows cannabinoids are effective for treating chronic pain in adults. Multiple systematic reviews and randomized controlled trials support cannabis use for neuropathic pain, cancer pain, and pain associated with multiple sclerosis.
The National Academies found chronic pain to be the condition with the strongest evidence for cannabis treatment. Both THC and CBD may contribute to pain relief through different mechanisms.
Pain efficacy based on systematic reviews and the 2017 National Academies report.
Research shows mixed evidence for cannabis and anxiety. CBD has shown promise in reducing anxiety in clinical studies, while high-THC products may worsen anxiety in some patients. Proper dosing and strain selection are critical for anxiety management.
Research suggests CBD may reduce anxiety without impairing function. Low-dose THC may help, but higher doses can trigger anxiety. Individual response varies significantly.
Anxiety research based on clinical trials and preclinical studies on CBD and THC.
Cannabis is proven effective for cancer-related symptoms like chemotherapy-induced nausea and cancer pain. Preclinical research on cannabinoids inhibiting tumor growth is promising but not yet proven in human clinical trials.
FDA-approved synthetic THC (dronabinol, nabilone) is used for chemotherapy nausea. Direct anti-cancer effects remain under investigation in laboratory settings.
Cancer research based on clinical trials and preclinical cancer research.
Federal Schedule I classification has historically limited US cannabis research by creating barriers to funding, access, and conducting clinical trials. However, over 53,000 cannabis studies exist on PubMed, and research is accelerating globally.
Recent policy changes including DEA rescheduling proposals may expand US research. Countries like Israel, Canada, and the Netherlands have conducted significant clinical research.
Research limitations based on federal drug scheduling and NIH funding data.
PubMed contains over 53,000 cannabis-related studies. Research libraries translate peer-reviewed cannabis studies into patient-friendly summaries with links to original sources, making complex research accessible to patients.
Look for research reviews that link to the original study on PubMed or the publishing journal and explain methodology, findings, and limitations in plain language.
Study count based on PubMed database search for cannabis research.
The endocannabinoid system (ECS) is a biological system discovered in the 1990s that regulates homeostasis throughout the body. The ECS includes CB1 and CB2 receptors, endogenous cannabinoids, and metabolic enzymes.
The ECS was discovered while researching how THC affects the body. It helps explain why cannabinoids have such wide-ranging therapeutic potential across many conditions.
ECS information based on foundational research by Mechoulam, Devane, and others.
Yes, over 600 active trials are registered on ClinicalTrials.gov studying conditions from epilepsy to PTSD to cancer symptoms. Trial enrollment is increasing as research barriers decrease and more states legalize.
Phase 2 and 3 trials for specific conditions are ongoing. Patients can search ClinicalTrials.gov to find studies recruiting participants near them.
Trial count based on ClinicalTrials.gov registered cannabis studies.
With over 53,000 cannabis studies published on PubMed, finding answers shouldn't require a medical degree. Our Research Library takes peer-reviewed studies and translates them into language patients can understand.
Each review explains what researchers studied, what they found, and most importantly—what it means for you. We're honest about limitations and always link to the original source so you can verify everything yourself.
Learn about our research methodology97% of patients agreed or strongly agreed that cannabis helped them decrease the amount of opioids they use, with 92% preferring cannabis over opioids for pain management.
Showing 75 research reviews
VER-01 (full-spectrum cannabis extract) shows potential as a new, safe and effective treatment for chronic low back pain.
Cannabis shows promise as a therapeutic option for Crohn's disease, demonstrating higher remission rates. However, quality of life was significantly better in the placebo group, highlighting the need for larger, standardized research studies.
In this landmark comparison of 90 trials with 22,028 patients, cannabis was found to be similarly effective to opioids for chronic pain relief, but with a critical advantage: patients on cannabis were 45% less likely to stop treatment due to adverse events compared to those on opioids.
In this rigorous 2024 trial, 150mg of nightly CBD was no better than placebo for most sleep measures in people with insomnia. While CBD users reported better well-being and showed slightly improved objective sleep efficiency, the primary sleep outcomes were not significantly different from placebo.
This 2024 systematic review of 15 studies found that most research shows 42-66% pain reduction with CBD or CBD+THC. However, 3 studies found no benefit, and the evidence overall is limited by small study numbers and varied methods.
These 2024 clinical practice guidelines, based on 70 studies, conclude that cannabis-based medicines show "moderate benefit" for chronic pain and also help related conditions like sleep problems and anxiety. The guidelines provide practical dosing and titration recommendations for clinicians.
THC significantly increases heart rate (~17 bpm), arterial stiffness, and reduces cardiac function—effects that could increase cardiovascular risk. CBD did NOT cause these cardiovascular effects. Smoking vs vaping THC made no difference.
Cannabinoids used for medical purposes in children and adolescents were associated with an increased risk of adverse events, including 3x higher withdrawal rates due to adverse events and nearly 2x higher serious adverse events compared to controls.
There was no benefit, perhaps worsened cognition and sleep, and there were many mild adverse events. The brief duration and strong placebo response limits interpretation of effects.
Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis may improve refractory chemotherapy-induced nausea and vomiting when added to standard antiemetics.
The study met both primary (GAD-7 and HAM-A scores) and secondary outcomes (CGI-I, CGI-S, PHQ-9 and PSQI scores). CBD significantly improved anxiety symptoms compared to placebo.
This comprehensive umbrella review of 101 meta-analyses found high-certainty evidence that CBD effectively reduces seizures in epilepsy, and cannabis-based medicines help chronic pain (30% pain reduction), MS spasticity, and IBD—but also identified clear risks during pregnancy, for mental health, and while driving.
If the research suggests cannabis might help your condition, our licensed physicians can evaluate whether you qualify for a medical marijuana card.
